Compare CULP & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | CTSO |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | CULP | CTSO |
|---|---|---|
| Price | $4.01 | $0.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 24.2K | ★ 140.8K |
| Earning Date | 12-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $207,391,000.00 | $36,979,520.00 |
| Revenue This Year | $1.93 | $11.93 |
| Revenue Next Year | $2.77 | $21.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $3.42 | $0.60 |
| 52 Week High | $5.94 | $1.61 |
| Indicator | CULP | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 49.15 | 56.90 |
| Support Level | $3.78 | $0.60 |
| Resistance Level | $3.89 | $0.85 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 55.56 | 88.00 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.